Multiparametric immunohistochemistry revealed a significantly lower microvascular density (CD31: 147 ± 48 vs. 287 ± 92; p = 0.001) and tumor cell proliferation (Ki-67: 3718 ± 998 vs. 5389 ± 1332; p = 0.007) in the therapy compared to the control group. Here, MKI67 is linked to neoplasm.